PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism

The transcription factor, PPAR delta is involved in suppressing inflammation, stimulating oligodendroglial biogenesis and myelination. Furthermore, activation of PPAR delta directly protects mitochondria against noxious stimuli and stimulates biogenesis of new mitochondria. PPAR delta activation dir...

Full description

Bibliographic Details
Published in:International Immunopharmacology
Main Authors: Altinoz, Meric A., Ozpinar, Aysel
Format: Article in Journal/Newspaper
Language:English
Published: 2019
Subjects:
Online Access:https://cris.maastrichtuniversity.nl/en/publications/8ee283ff-21d5-4fed-8ef3-bb402e078ed3
https://doi.org/10.1016/j.intimp.2019.01.057
id ftumaastrichtcri:oai:cris.maastrichtuniversity.nl:publications/8ee283ff-21d5-4fed-8ef3-bb402e078ed3
record_format openpolar
spelling ftumaastrichtcri:oai:cris.maastrichtuniversity.nl:publications/8ee283ff-21d5-4fed-8ef3-bb402e078ed3 2023-05-15T16:06:47+02:00 PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism Altinoz, Meric A. Ozpinar, Aysel 2019-04 https://cris.maastrichtuniversity.nl/en/publications/8ee283ff-21d5-4fed-8ef3-bb402e078ed3 https://doi.org/10.1016/j.intimp.2019.01.057 eng eng info:eu-repo/semantics/closedAccess Altinoz , M A & Ozpinar , A 2019 , ' PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism ' , International Immunopharmacology , vol. 69 , pp. 245-256 . https://doi.org/10.1016/j.intimp.2019.01.057 Erucic acid PPAR-delta Multiple sclerosis Alzheimer's Disease Neuroprotection Remyelination PROLIFERATOR-ACTIVATED RECEPTOR CENTRAL-NERVOUS-SYSTEM X-LINKED ADRENOLEUKODYSTROPHY LORENZOS OIL COGNITIVE IMPAIRMENT BRASSICA-JUNCEA CELLS BRAIN EXPRESSION MACROPHAGES article 2019 ftumaastrichtcri https://doi.org/10.1016/j.intimp.2019.01.057 2022-07-19T09:11:29Z The transcription factor, PPAR delta is involved in suppressing inflammation, stimulating oligodendroglial biogenesis and myelination. Furthermore, activation of PPAR delta directly protects mitochondria against noxious stimuli and stimulates biogenesis of new mitochondria. PPAR delta activation directly inhibits neuronal cell death and reduces both the level and neurotoxicity of Amyloid-beta fibers in Alzheimer's Disease (AD) models. Among the important ligands of PPAR delta is erucic acid (EA, 22:1 n9), an edible omega-9 fatty acid and a component of Lorenzo's oil, which is used in the treatment of adrenoleukodystrophy (ALD). Nonetheless, the feature of PPAR delta-erucic acid interaction has not been extensively studied. EA can also be converted to nervonic acid, an important component of myelin. Hence, EA may act as an anti-inflammatory and remyelinating agent, which might be important in the management of another demyelinating disease, multiple sclerosis (MS). Oxidative injury and mitochondrial damage are among the features of ALD. Direct inhibitory effects of EA was observed on lipid peroxidation and inflammatory enzymes, neutrophil elastase and thrombin. EA also induces catalase, a potent antioxidant peroxisomal enzyme. However, EA is claimed to be a cardiotoxic molecule, yet these studies were mostly performed on rats, which do not efficiently metabolize EA. Further, EA is largely consumed by Asian population and Greenland Eskimos with no signs of cardiac damage. In this review, we shed light on the potential theraputic role of EA in MS and AD by blocking neural cell death, mitigating neuroinflammation and/or inducing myelination. Article in Journal/Newspaper eskimo* Greenland Maastricht University Research Publications Greenland International Immunopharmacology 69 245 256
institution Open Polar
collection Maastricht University Research Publications
op_collection_id ftumaastrichtcri
language English
topic Erucic acid
PPAR-delta
Multiple sclerosis
Alzheimer's Disease
Neuroprotection
Remyelination
PROLIFERATOR-ACTIVATED RECEPTOR
CENTRAL-NERVOUS-SYSTEM
X-LINKED ADRENOLEUKODYSTROPHY
LORENZOS OIL
COGNITIVE IMPAIRMENT
BRASSICA-JUNCEA
CELLS
BRAIN
EXPRESSION
MACROPHAGES
spellingShingle Erucic acid
PPAR-delta
Multiple sclerosis
Alzheimer's Disease
Neuroprotection
Remyelination
PROLIFERATOR-ACTIVATED RECEPTOR
CENTRAL-NERVOUS-SYSTEM
X-LINKED ADRENOLEUKODYSTROPHY
LORENZOS OIL
COGNITIVE IMPAIRMENT
BRASSICA-JUNCEA
CELLS
BRAIN
EXPRESSION
MACROPHAGES
Altinoz, Meric A.
Ozpinar, Aysel
PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism
topic_facet Erucic acid
PPAR-delta
Multiple sclerosis
Alzheimer's Disease
Neuroprotection
Remyelination
PROLIFERATOR-ACTIVATED RECEPTOR
CENTRAL-NERVOUS-SYSTEM
X-LINKED ADRENOLEUKODYSTROPHY
LORENZOS OIL
COGNITIVE IMPAIRMENT
BRASSICA-JUNCEA
CELLS
BRAIN
EXPRESSION
MACROPHAGES
description The transcription factor, PPAR delta is involved in suppressing inflammation, stimulating oligodendroglial biogenesis and myelination. Furthermore, activation of PPAR delta directly protects mitochondria against noxious stimuli and stimulates biogenesis of new mitochondria. PPAR delta activation directly inhibits neuronal cell death and reduces both the level and neurotoxicity of Amyloid-beta fibers in Alzheimer's Disease (AD) models. Among the important ligands of PPAR delta is erucic acid (EA, 22:1 n9), an edible omega-9 fatty acid and a component of Lorenzo's oil, which is used in the treatment of adrenoleukodystrophy (ALD). Nonetheless, the feature of PPAR delta-erucic acid interaction has not been extensively studied. EA can also be converted to nervonic acid, an important component of myelin. Hence, EA may act as an anti-inflammatory and remyelinating agent, which might be important in the management of another demyelinating disease, multiple sclerosis (MS). Oxidative injury and mitochondrial damage are among the features of ALD. Direct inhibitory effects of EA was observed on lipid peroxidation and inflammatory enzymes, neutrophil elastase and thrombin. EA also induces catalase, a potent antioxidant peroxisomal enzyme. However, EA is claimed to be a cardiotoxic molecule, yet these studies were mostly performed on rats, which do not efficiently metabolize EA. Further, EA is largely consumed by Asian population and Greenland Eskimos with no signs of cardiac damage. In this review, we shed light on the potential theraputic role of EA in MS and AD by blocking neural cell death, mitigating neuroinflammation and/or inducing myelination.
format Article in Journal/Newspaper
author Altinoz, Meric A.
Ozpinar, Aysel
author_facet Altinoz, Meric A.
Ozpinar, Aysel
author_sort Altinoz, Meric A.
title PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism
title_short PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism
title_full PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism
title_fullStr PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism
title_full_unstemmed PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism
title_sort ppar-δ and erucic acid in multiple sclerosis and alzheimer's disease. likely benefits in terms of immunity and metabolism
publishDate 2019
url https://cris.maastrichtuniversity.nl/en/publications/8ee283ff-21d5-4fed-8ef3-bb402e078ed3
https://doi.org/10.1016/j.intimp.2019.01.057
geographic Greenland
geographic_facet Greenland
genre eskimo*
Greenland
genre_facet eskimo*
Greenland
op_source Altinoz , M A & Ozpinar , A 2019 , ' PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's Disease. Likely benefits in terms of immunity and metabolism ' , International Immunopharmacology , vol. 69 , pp. 245-256 . https://doi.org/10.1016/j.intimp.2019.01.057
op_rights info:eu-repo/semantics/closedAccess
op_doi https://doi.org/10.1016/j.intimp.2019.01.057
container_title International Immunopharmacology
container_volume 69
container_start_page 245
op_container_end_page 256
_version_ 1766402802323554304